DeutschNewstral
Article
bizjournals.com on 2016-09-15 19:59
Intarcia raises $215 million as it gets ready to seek FDA OK for experimental diabetes treatment
Related news
- FDA rejects AstraZeneca's experimental diabetes therapybizjournals.com
FDA Approves Lilly/Ingelheim Diabetes Treatmentinsideindianabusiness.com- Intarcia reports little progress on diabetes treatment one year after FDA rejectionbizjournals.com
- MDBV discloses FDA concerns about experimental peanut allergy treatmentmarketwatch.com
FDA skeptical of experimental ALS treatment pushed by patient advocatesSeattle Times
FDA panel backs ‘experimental’ treatment for peanut allergyNew York Post
Experimental COVID-19 treatment given to Trump gets FDA authorizationKVUE News
FDA advisers vote against experimental ALS treatment pushed by patientstimesfreepress.com- MZafgen's IND for diabetes treatment placed on hold by FDAmarketwatch.com
FDA Rejects Oral Treatment for Type 1 Diabeteswsj.com- MAcorda Therapeutics' Inbrija Parkinson's disease treatment gets FDA OKmarketwatch.com
FDA gives early OK to combo cancer treatmentThe Salt Lake Tribune- Aclaris' treatment for common skin condition gets FDA OKbizjournals.com
- MRoche gets FDA OK for multiple sclerosis treatmentmarketwatch.com
- Teva gets FDA OK for rare disease treatmentbizjournals.com
- Intarcia clears final trial hurdle before seeking FDA approval, plans hiring pushbizjournals.com
- MSigns point to FDA approval for Biogen’s experimental Alzheimer’s disease treatment, though there are skepticsmarketwatch.com
- FDA gives emergency clearance to Eli Lilly’s experimental COVID-19 antibody treatmentNew York Post
Health experts back experimental treatment for kids with peanut allergy; FDA to have final sayFOX 8 News Cleveland